Affiliation:
1. A.Tsyb Medical Radiological Research Center, Obninsk, Russia
2. A.F. Tsyb Medical Radiological Research Center
Abstract
The article reviews domestic and foreign literature on the use of radiation therapy in the treatment of medullary thyroid cancer. The possibilities of various radiation methods in the treatment of patients with distant metastases are shown. In addition to classical types of remote irradiation, data are presented on the possibilities of radionuclide therapy (peptide-receptor therapy with somatostatin analogs and radionuclide therapy with osteotropic drugs for bone metastases). Methods of combined therapy with the use of osteomodifying agents, targeted drugs and other methods are described, which make it possible to increase the effectiveness of treatment of patients with medullary thyroid cancer with bone metastases.
Publisher
Infra-M Academic Publishing House
Subject
Nuclear Energy and Engineering
Reference47 articles.
1. Каприн А.Д., Старинский В.В., Петрова Г.В. и др. Состояние онкологической помощи населению России. Москва. 2017.[Kaprin AD, Starinsky VV, Petrova GV. State of oncological care for the population of Russia. Moscow. 2017 (In Russian).], Kaprin A.D., Starinskiy V.V., Petrova G.V. i dr. Sostoyanie onkologicheskoy pomoschi naseleniyu Rossii. Moskva. 2017.[Kaprin AD, Starinsky VV, Petrova GV. State of oncological care for the population of Russia. Moscow. 2017 (In Russian).]
2. Asimakopoulos P, Nixon IJ, Shaha AR. Differentiated and Medullary Thyroid Cancer: Surgical Management of Cervical Lymph Nodes. Clin Oncol (R Coll Radiol). 2017 May;29(5):283-89. DOI: 10.1016/j.clon.2017.01.001. Epub 2017 Jan 13. Review. PubMed PMID: 28094086; PubMed Central PMCID: PMC5541897., Asimakopoulos P, Nixon IJ, Shaha AR. Differentiated and Medullary Thyroid Cancer: Surgical Management of Cervical Lymph Nodes. Clin Oncol (R Coll Radiol). 2017 May;29(5):283-89. DOI: 10.1016/j.clon.2017.01.001. Epub 2017 Jan 13. Review. PubMed PMID: 28094086; PubMed Central PMCID: PMC5541897.
3. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006 Nov 1;107(9):2134-42. PubMed PMID: 17019736., Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006 Nov 1;107(9):2134-42. PubMed PMID: 17019736.
4. Румянцев ПО, Румянцева УВ. Таргетная терапия вандетанибом медуллярного рака щитовидной железы у детей и подростков. Онкопедиатрия, 2015;(2):115-120.[Rumyantsev PO, Rumyantseva UV. Targeted Therapy with Vandetanib Medullary Thyroid Carcinoma in Children and Adolescents. Oncopediatrics. 2015;2(2):115-20. DOI: 10.15690/onco. v2i2.1342], Rumyancev PO, Rumyanceva UV. Targetnaya terapiya vandetanibom medullyarnogo raka schitovidnoy zhelezy u detey i podrostkov. Onkopediatriya, 2015;(2):115-120.[Rumyantsev PO, Rumyantseva UV. Targeted Therapy with Vandetanib Medullary Thyroid Carcinoma in Children and Adolescents. Oncopediatrics. 2015;2(2):115-20. DOI: 10.15690/onco. v2i2.1342]
5. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73. PubMed PMID: 9578814., Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73. PubMed PMID: 9578814.